Trial Profile
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Celator Pharmaceuticals; Jazz Pharmaceuticals Inc
- 12 Dec 2023 Results of a PopPKPD model analysis using data from three clinical studies: NCT00389428, NCT02238925 and NCT01696084 presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results of post hoc analysis assessing 5 year trial data presented at the 28th Congress of the European Haematology Association
- 15 Jun 2023 Results of a post-hoc analysis reporting 5-year follow-up data presented at the 28th Congress of the European Haematology Association